Most cancer vaccines rely on dendritic cells to activate tumor antigen-specific CD4+ and CD8+ T cells, as well as antibody-producing B cells capable of long-lasting antitumor responses through the generation of immunological memory [2,28,29,30,31]. This evidence concerns the gene CD8A and neoplasm.